Effects of Hemantane upon the level of lipid peroxidation in brain in experimental parkinsonian syndrome
In two animaL modeLs of parkinsonian syndrome - induced by 1-methyL-4-phenyL-1,2,3,6-tetrahydropiridine (MPTP) in C57BL/6 mice and 6-hydroxidopamine (6-OHDA) in rats noveL antiparkinsonian drug hemantane was shown to reduce the increase of brain LeveL of Lipid peroxidation caused by both neurotoxine...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
LLC "Publisher OKI",
2016-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1a792802021e45d2a1e8e9ec8ebd5cd2 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a E. A. Ivanova |e author |
| 700 | 1 | 0 | |a I. G. Kapitsa |e author |
| 700 | 1 | 0 | |a N. N. Zolotov |e author |
| 700 | 1 | 0 | |a E. A. Valdman |e author |
| 700 | 1 | 0 | |a A. V. Nepoklonov |e author |
| 700 | 1 | 0 | |a K. N. Kolyasnikova |e author |
| 700 | 1 | 0 | |a T. A. Voronina |e author |
| 245 | 0 | 0 | |a Effects of Hemantane upon the level of lipid peroxidation in brain in experimental parkinsonian syndrome |
| 260 | |b LLC "Publisher OKI", |c 2016-09-01T00:00:00Z. | ||
| 500 | |a 2587-7836 | ||
| 500 | |a 2686-8830 | ||
| 520 | |a In two animaL modeLs of parkinsonian syndrome - induced by 1-methyL-4-phenyL-1,2,3,6-tetrahydropiridine (MPTP) in C57BL/6 mice and 6-hydroxidopamine (6-OHDA) in rats noveL antiparkinsonian drug hemantane was shown to reduce the increase of brain LeveL of Lipid peroxidation caused by both neurotoxines. In prefrontaL cortex and striatum of mice which were treated with hemantane 10 mg/kg 5 days before MPTP and 5 days together with MPTP and in rats which received hemantane during 21 days after 6-OHDA injection in mediaL forebrain bundLe the LeveLs of maLondiaLdehyde and conjugated dienes were significantLy Lower than in untreated animaLs. The data obtained is consistent with antioxidant properties of hemantane. | ||
| 546 | |a RU | ||
| 690 | |a гимантан | ||
| 690 | |a модели паркинсонического синдрома | ||
| 690 | |a мфтп | ||
| 690 | |a 6-года | ||
| 690 | |a перекисное окисление липидов | ||
| 690 | |a малоновый альдегид | ||
| 690 | |a диеновые конъюгаты | ||
| 690 | |a hemantane | ||
| 690 | |a experimental parkinsonian syndrome | ||
| 690 | |a mptp | ||
| 690 | |a 6-ohda | ||
| 690 | |a lipid peroxidation | ||
| 690 | |a malondialdehyde | ||
| 690 | |a conjugated dienes | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Фармакокинетика и Фармакодинамика, Vol 0, Iss 3, Pp 9-12 (2016) | |
| 787 | 0 | |n https://www.pharmacokinetica.ru/jour/article/view/177 | |
| 787 | 0 | |n https://doaj.org/toc/2587-7836 | |
| 787 | 0 | |n https://doaj.org/toc/2686-8830 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1a792802021e45d2a1e8e9ec8ebd5cd2 |z Connect to this object online. |